PDL BioPharma, Inc. Payments for Repurchase of Common Stock
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- PDL BioPharma, Inc. payments for repurchase of common stock for the quarter ending 2020-06-30 was $20.15M, a 25.32% decline year-over-year.
- PDL BioPharma, Inc. payments for repurchase of common stock for the quarter ending 2020-03-31 was $19.23M, a 56.59% decline year-over-year.
- PDL BioPharma, Inc. payments for repurchase of common stock for the quarter ending 2019-12-31 was $11.01M, a 54.34% decline year-over-year.
- PDL BioPharma, Inc. payments for repurchase of common stock for the quarter ending 2019-09-30 was $4.63M, a 231.30% increase year-over-year.
- PDL BioPharma, Inc. payments for repurchase of common stock for fiscal 2019 was $86.90M, a 76.95% increase from fiscal 2018.
- PDL BioPharma, Inc. payments for repurchase of common stock for fiscal 2018 was $49.11M.
- PDL BioPharma, Inc. payments for repurchase of common stock for fiscal 2016 was $0.00.
- PDL BioPharma, Inc. payments for repurchase of common stock for fiscal 2015 was $0.00.
| Period end | Payments for Repurchase of Common Stock 3 month | Payments for Repurchase of Common Stock 12 month |
|---|---|---|
| 2020-06-30 | $20.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $55.01M derived: sum of 4 quarters · filed 2021-03-29 |
| 2020-03-31 | $19.23M 10-Q · filed 2020-05-11 | $61.84M derived: sum of 4 quarters · filed 2021-03-29 |
| 2019-12-31 | $11.01M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | $86.90M 10-K · filed 2021-03-29 |
| 2019-09-30 | $4.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-13 | $100.00M derived: sum of 4 quarters · filed 2021-03-29 |
| 2019-06-30 | $26.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $96.77M derived: sum of 4 quarters · filed 2021-03-29 |
| 2019-03-31 | $44.29M 10-Q · filed 2020-05-11 | $89.84M derived: sum of 4 quarters · filed 2021-03-29 |
| 2018-12-31 | $24.11M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | $49.11M 10-K · filed 2021-03-29 |
| 2018-09-30 | $1.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $25.00M derived: sum of 4 quarters · filed 2020-06-29 |
| 2018-06-30 | $20.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $23.60M derived: sum of 4 quarters · filed 2020-06-29 |
| 2018-03-31 | $3.56M 10-Q · filed 2019-05-09 | $25.91M derived: sum of 4 quarters · filed 2020-06-29 |
| 2017-12-31 | $0.00 derived: 8-K 12 month − 10-Q 9 month · filed 2020-06-29 | $30.00M 8-K · filed 2020-06-29 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $30.00M derived: sum of 4 quarters · filed 2019-03-15 |
| 2017-06-30 | $22.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $30.00M derived: sum of 4 quarters · filed 2019-03-15 |
| 2017-03-31 | $7.65M 10-Q · filed 2018-05-09 | $7.65M derived: sum of 4 quarters · filed 2019-03-15 |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-15 | $0.00 10-K · filed 2019-03-15 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-13 | |
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | |
| 2016-03-31 | $0.00 10-Q · filed 2017-05-03 | |
| 2015-12-31 | $0.00 10-K · filed 2018-03-16 |